"Le CH de Saint-Brieuc dispense des soins spécialisés pour l'ensemble du département des Cotes d'Armor. Il est, par sa capacité, son activité et son plateau technique, le 3ème établissement public de santé breton, après les CHU de Rennes et Brest. Il assume les fonctions d’hôpital de proximité pour une population d’environ 100 000 habitants. Il dispose de 1247 lits et places répartis sur l'hôpital Yves le Foll (667 lits et 96 places MCO-SSR) et le Centre gériatrique des Capucins (472 lits et 12 places). Le CH de Saint-Brieuc est également l'établissement support du Groupement Hospitalier du Territoire d'Armor lequel regroupe les hôpitaux de Guingamp, Lannion-Trestel, Paimpol, Tréguier, Saint-Brieuc et Penthièvre et Poudouvre (CH2P)."

During the past decade, CH Saint Brieuc conducted 77 clinical trials. In the 10-year time frame, 77 clinical trials started and 5 clinical trials were completed, i.e. on average, 6.5% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 2 clinical trials were completed. i.e. 5.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH Saint Brieuc" #1 sponsor was "Rennes University Hospital" with 18 trials, followed by "University Hospital, Brest" with 13 trials sponsored, "Nantes University Hospital" with 11 trials sponsored, "Intergroupe Francophone de Cancerologie Thoracique" with 8 trials sponsored and "Intergroupe Francophone du Myelome" with 8 trials sponsored. Other sponsors include 63 different institutions and companies that sponsored additional 45 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH Saint Brieuc" #1 collaborator was "Ministry of Health, France" with 5 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "University Hospital, Tours" with 3 trials as a collaborator, "Amgen" with 2 trials as a collaborator and "Bristol-Myers Squibb" with 2 trials as a collaborator. Other collaborators include 51 different institutions and companies that were collaborators in the rest 57 trials.

According to Clinical.Site data, the most researched conditions in "CH Saint Brieuc" are "Multiple Myeloma" (8 trials), "Atrial Fibrillation" (3 trials), "Carcinoma, Non-Small-Cell Lung" (3 trials), "Emergencies" (3 trials) and "HIV Infections" (3 trials). Many other conditions were trialed in "CH Saint Brieuc" in a lesser frequency.

Most popular intervention types in "CH Saint Brieuc" are "Drug" (58 trials), "Other" (26 trials), "Procedure" (15 trials), "Device" (7 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Cyclophosphamide" (4 trials), "Guselkumab" (3 trials), "placebo" (3 trials) and "Amprenavir/ritonavir" (2 trials). Other intervention names were less common.

The vast majority of trials in "CH Saint Brieuc" are 117 trials for "All" genders, 4 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 28 active trials in "CH Saint Brieuc". 1 are not yet recruiting, 20 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 68 completed trials in CH Saint Brieuc, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in CH Saint Brieuc, 1 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 28 trials that are defined as “Not Applicable".

CH Saint Brieuc has several departments that took part in Clinical trials: "Hopital Yves Le Foll; Hematologie Oncologie" - 2 trials